Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.

Details

Serval ID
serval:BIB_7D2E0AB92C30
Type
Article: article from journal or magazin.
Collection
Publications
Title
Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.
Journal
Archives of dermatology
Author(s)
Guenova E., Teske A., Fehrenbacher B., Hoerber S., Adamczyk A., Schaller M., Hoetzenecker W., Biedermann T.
ISSN
1538-3652 (Electronic)
ISSN-L
0003-987X
Publication state
Published
Issued date
10/2011
Peer-reviewed
Oui
Volume
147
Number
10
Pages
1203-1205
Language
english
Notes
Publication types: Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Interleukin (IL)-23 is involved in the pathogenesis of the chronic inflammatory Crohn disease. Pyoderma gangrenosum (PG) is often associated with and can even be the first manifestation of this disease and has abundant neutrophilic infiltration. Because IL-23 plays a critical role in driving inflammation associated with IL-17 production and especially neutrophil recruitment, we suspect that PG might be driven by a pathogenetic mechanism similar to that of inflammatory bowel diseases or psoriasis.
Tissue sample analysis showed highly elevated expression of IL-23 on both transcriptional and protein level in a recalcitrant PG lesion. On the basis on these data, a treatment targeting the p40 subunit of the heterodimeric IL-23 with the monoclonal antibody ustekinumab was started. Therapy with ustekinumab resulted in a significant decrease of IL-23 expression in PG and healing after 14 weeks of treatment. No relapse occurred in a 6-month follow-up period.
Our data provide evidence of an IL-23-dominated inflammatory infiltrate in PG. This might specify a new concept for PG pathophysiology and suggests a possibility for using ustekinumab as a therapeutic agent in this disease.
Keywords
Adult, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents/therapeutic use, Interleukin-23/antagonists & inhibitors, Interleukin-23/biosynthesis, Molecular Targeted Therapy, Pyoderma Gangrenosum/diagnosis, Pyoderma Gangrenosum/drug therapy, Pyoderma Gangrenosum/pathology, Tacrolimus/therapeutic use, Treatment Outcome, Ustekinumab
Pubmed
Web of science
Open Access
Yes
Create date
27/08/2020 14:00
Last modification date
02/09/2020 5:26
Usage data